» Articles » PMID: 26213307

Beneficial Protective Effect of Pramipexole on Light-induced Retinal Damage in Mice

Overview
Journal Exp Eye Res
Specialty Ophthalmology
Date 2015 Jul 28
PMID 26213307
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the effects of pramipexole, a potent dopamine receptor D2/D3 agonist, on light-induced retinal damage in mice, H2O2-induced retinal pigment epithelium ARPE-19 cell injury in humans, and hydroxyl radical scavenging activity in a cell-free system. Pramipexole (0.1 and 1 mg/kg body weight) was orally administered to mice 1 h before light exposure (5000 lux, 2 h). Electrophysiological and morphologic studies were performed to evaluate the effects of the pramipexole on light-induced retinal damage in mice. Pramipexole significantly prevented the reduction of the a- and b-wave electroretinogram (ERG) amplitudes caused by light exposure in a dose-dependent manner. In parallel, damage to the inner and outer segments (IS/OS) of the photoreceptors, loss of photoreceptor nuclei, and the number of Tdt-mediated dUTP nick-end labeling (TUNEL)-positive cells in the outer nuclear layer (ONL) caused by light exposure were notably ameliorated by pramipexole. Additionally, pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro in a concentration-dependent manner. The effect of pramipexole was significant at concentrations of 10(-6) M or higher. Pramipexole also significantly prevented H2O2-induced activation of caspases-3/7 and the intracellular accumulation of reactive oxygen species (ROS) in a concentration-dependent manner ranging from 10(-5) to 10(-3) M. Furthermore, pramipexole increased the scavenging activity toward a hydroxyl radical generated from H2O2 in a Fenton reaction. Our results suggest that pramipexole protects against light-induced retinal damage as an antioxidant and that it may be a novel and effective therapy for retinal degenerative disorders, such as dry age-related macular degeneration.

Citing Articles

A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.

Leinonen H, Zhang J, Occelli L, Seemab U, Choi E, L P Marinho L Nat Commun. 2024; 15(1):5943.

PMID: 39009597 PMC: 11251169. DOI: 10.1038/s41467-024-50033-5.


Halofuginone prevents outer retinal degeneration in a mouse model of light-induced retinopathy.

Miwa Y, Lee D, Shoda C, Jeong H, Negishi K, Kurihara T PLoS One. 2024; 19(3):e0300045.

PMID: 38536853 PMC: 10971573. DOI: 10.1371/journal.pone.0300045.


Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision.

Karamali F, Behtaj S, Babaei-Abraki S, Hadady H, Atefi A, Savoj S J Transl Med. 2022; 20(1):572.

PMID: 36476500 PMC: 9727916. DOI: 10.1186/s12967-022-03738-4.


Antioxidants for the Treatment of Retinal Disease: Summary of Recent Evidence.

Wang P, Chin E, Almeida D Clin Ophthalmol. 2021; 15:1621-1628.

PMID: 33907376 PMC: 8064715. DOI: 10.2147/OPTH.S307009.


The Dopaminergic Neuronal System Regulates the Inflammatory Status of Mouse Lacrimal Glands in Dry Eye Disease.

Ji Y, Kang H, Song J, Jun J, Han K, Kim T Invest Ophthalmol Vis Sci. 2021; 62(4):14.

PMID: 33844826 PMC: 8039574. DOI: 10.1167/iovs.62.4.14.